浙江医药股份有限公司 关于召开 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：600216 证券简称：浙江医药 公告编号：2024-011 （一）会议召开时间：2024 年 05 月 23 日下午 13:00-14:30 （二）会议召开地点：上证路演中心（网址：http://roadshow.sseinfo.com/） 会议召开时间：2024 年 05 月 23 日(星期四)下午 13:00-14:30 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频播放和网络互动 （三）会议召开方式：上证路演中心视频播放和网络互动 三、 参加人员 公司副董事长、总裁吕春雷先生，独立董事裘益政先生，财务总监李齐融女 士，董事会秘书邵旻之先生。 投资者可于 2024 年 05 月 16 日(星期四)至 05 月 22 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏 ...

Investment Rating - The report maintains a "Buy" rating for Zhejiang Medicine (600216.SH) [11][16] Core Views - The vitamin market has shown signs of recovery, with significant performance improvement in Q1 2024. The company is focusing on R&D and the orderly progress of its pharmaceutical business [11][16] - The company's revenue for 2023 was 7.794 billion yuan, a decrease of 4% year-on-year, while the net profit attributable to shareholders was 430 million yuan, down 20% year-on-year. However, Q4 2023 saw a net profit of 130 million yuan, a 133% increase year-on-year [16] - In Q1 2024, the company achieved a revenue of 2.2 billion yuan, a 12% increase year-on-year, and a net profit of 110 million yuan, a 3% decrease year-on-year [16] Financial Performance Summary - The company's projected net profits for 2024, 2025, and 2026 are 484 million yuan (down 36%), 638 million yuan (down 29%), and 746 million yuan, respectively, with corresponding EPS of 0.50, 0.66, and 0.77 yuan [11][12] - Revenue is expected to grow from 8.623 billion yuan in 2024 to 10.599 billion yuan in 2026, with growth rates of 10.63%, 10.79%, and 10.95% [12] - The company's gross profit margin is projected to improve from 32.1% in 2024 to 35.5% in 2026 [12] R&D and Product Development - The company has increased its R&D investment, with R&D expenses reaching 860 million yuan in 2023, a 6% increase year-on-year [16] - New products are being developed, with several projects progressing through clinical trials and regulatory approvals, including various formulations and active pharmaceutical ingredients [16]

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------|-----------------------------|-------|--------|--------|----------|-------------------------------------------------------------------|-------------------------------|-------------|-------------|---------------|-------------| | 利润表（百万元） \n营业收入 8,116 7,794 8,623 9,553 10,599 | 2022 2023 2024E 2025E 2026E | | | | | 资产负债表（百万元） \n总资产 12,433 12,780 14,272 15,392 16,710 | 2022 2 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥7.79 billion, a decrease of 3.96% compared to ¥8.12 billion in 2022[38]. - Net profit attributable to shareholders for 2023 was approximately ¥429.64 million, down 20.37% from ¥539.57 million in 2022[38]. - The net profit after deducting non-recurring gains and losses was approximately ¥153.30 million, a significant decline of 70.19% from ¥514.24 million in 2022[38]. - The overall operating revenue decreased by 3.96% to ¥7,794,145,971.37, with operating costs decreasing by 0.91% to ¥5,269,878,689.98[95]. - The gross profit margin decreased by 2.26 percentage points to 32.56% compared to the previous year[98]. - The net profit attributable to the parent company's shareholders for 2023 is CNY 429,639,626.26, with the parent company's net profit at CNY 610,537,146.18[117]. - Basic earnings per share (EPS) for 2023 was 0.45 RMB, a decline of 19.64% from 0.56 RMB in 2022[46]. - The weighted average return on equity (ROE) decreased to 4.54% in 2023, down 1.45 percentage points from 5.99% in 2022[46]. Research and Development - Research and development expenses reached ¥860,072,434.06, representing 11.03% of total operating income, with no capitalized R&D expenditures[16]. - The company employed 866 R&D personnel, accounting for 13.91% of the total workforce, with 28 holding doctoral degrees and 167 holding master's degrees[27]. - Research and development expenses increased by 6.28% to ¥860,072,434.06, indicating a focus on innovation[95]. - R&D investment for the anti-Her2-ADC project was 12,272.09 million RMB, accounting for 1.57% of operating revenue, with a year-on-year decrease of 21.65%[135]. - R&D investment for the apple acid naphthomycin and injection project was 8,471.92 million RMB, accounting for 1.09% of operating revenue, with a year-on-year increase of 21.03%[135]. - R&D investment for new formulations was 1,721.60 million RMB, accounting for 0.22% of operating revenue, with a year-on-year decrease of 48.56%[135]. - R&D investment for raw material drug process and quality research was 2,013.19 million RMB, accounting for 0.26% of operating revenue, with a year-on-year increase of 22.20%[135]. - The company is actively engaged in research and development of new products and technologies to drive future growth[38]. Costs and Expenses - Total sales expenses for the reporting period amounted to ¥1,045,588,220.72, an increase of 17.41% compared to the previous year[15]. - Financial expenses decreased by 53.94% to -¥17,488,438.76, compared to -¥37,966,060.26 in the previous year[15]. - Management expenses increased by 3.04% to ¥445,186,095.66 from ¥432,066,700.89 year-on-year[15]. - Raw material costs for life nutrition products decreased by 19.54% to ¥1,319,115,043.90, accounting for 25.20% of total costs[28]. - Total manufacturing costs for pharmaceutical manufacturing products increased by 6.73% to ¥358,388,349.38, representing 6.85% of total costs[28]. - The total cost of medical commercial products was ¥2,143,849,737.29, which is a 5.58% increase compared to the previous year[30]. - The overall cost decreased by 0.51% to ¥5,235,009,431.80, with the previous year's total at ¥5,261,603,719.61[28]. - The cost of the apple acid nano antibiotic series increased by 149.65% to ¥113,100,788.46, representing 2.16% of total costs[30]. - The total cost for the other category rose by 12.60% to ¥452,746,783.50, accounting for 8.65% of total costs[30]. - The labor cost for pharmaceutical manufacturing products increased by 20.57% to ¥91,085,316.06, representing 1.74% of total costs[28]. Market and Sales - The top five customers contributed ¥115,868.49 million to sales, making up 14.87% of total annual sales, with no sales to related parties[21]. - Domestic sales revenue reached ¥5,601,204,363.19, a year-on-year increase of 4.75%, while foreign sales revenue was ¥2,160,829,972.03, a decrease of 20.72%[90]. - The sales of life nutrition products accounted for 41.99% of total revenue, totaling ¥327,264.20 million, a decrease of 14.80% year-on-year[94]. - The company is expanding its life nutrition products into "Belt and Road" countries to offset declining profitability in traditional markets[88]. - The company has established a relatively complete sales service network in North America, Europe, and South America for its pharmaceutical raw materials, primarily through self-export[75]. - The company has covered over 25,000 pharmacy terminals in China, achieving effective coverage in all regions except Tibet, with stable growth in online sales through platforms like Tmall and JD[138]. Cash Flow and Assets - The net cash flow from operating activities increased by 21.84% to approximately ¥634.31 million in 2023, compared to ¥520.60 million in 2022[38]. - The total assets at the end of 2023 were approximately ¥12.78 billion, reflecting a 2.79% increase from ¥12.43 billion at the end of 2022[38]. - The net assets attributable to shareholders increased by 4.00% to approximately ¥9.63 billion at the end of 2023, compared to ¥9.26 billion at the end of 2022[38]. - Cash received from operating activities increased by 70.46% to CNY 173,042,753.68 compared to the same period last year[104]. - Cash flow from the disposal of fixed assets surged by 2324.60% to CNY 174,476,876.29, primarily due to compensation received from the relocation of a vitamin factory[104]. - The company reported a significant increase in other receivables, rising by 255.05% to CNY 239,136,451.64[109]. Governance and Compliance - The company ensures compliance with information disclosure obligations, providing equal access to information for all shareholders[122]. - There are no significant differences between the company's governance practices and the regulations set by the China Securities Regulatory Commission[122]. - The company is committed to maintaining transparency and accuracy in its financial reporting and disclosures[122]. - The board of directors has designated a secretary and office to oversee information disclosure and shareholder inquiries[122]. - The company has plans to revise its Articles of Association and improve internal control systems as part of its governance strategy[122]. - The company continues to focus on compliance with legal and regulatory requirements in its governance practices[122]. - The audit committee approved the 2023 semi-annual report, confirming compliance with legal and regulatory requirements[150]. Strategic Initiatives - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming fiscal year[38]. - The company plans to continue expanding into Southeast Asian markets while consolidating its presence in Europe and the United States[63]. - The company is actively pursuing strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers and acquisitions[127]. - The company has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in production costs by the end of the fiscal year[127]. - The company has established various training programs, including management and compliance training, to enhance employee capabilities[158]. Environmental and Social Responsibility - The company invested 11,454.48 million yuan in environmental protection during the reporting period[194]. - The total wastewater discharge was 69.098 million tons, with COD emissions of 110.67 tons and ammonia nitrogen emissions of 3.18 tons[200]. - The company has established environmental protection mechanisms and is classified as a key pollutant discharge unit[200].

证券代码：600216 证券简称：浙江医药 公告编号：2024-004 浙江医药股份有限公司 第九届十三次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 浙江医药股份有限公司第九届十三次监事会会议于 2024 年 4 月 25 日上午在 浙江医药总部 1 号楼 401 会议室，以现场与视频通讯表决相结合的方式召开。本 次会议的通知和材料于 2024 年 4 月 1 日以专人送达或电子邮件方式发出。会议 应参加监事五人，实际参加监事五人，监事吴逸园先生通过视频方式出席会议。 会议由监事长吴逸园先生主持，会议符合《公司法》和《公司章程》的有关规定 和要求。 二、监事会会议审议情况 监事会认为，公司 2023 年度利润分配预案的决策程序、利润分配的形式符 合《公司章程》。此利润分配预案充分考虑各方面因素，不存在损害中小股东利 益的情形，符合公司经营现状，有利于公司持续、稳定、健康发展。 本议案需提交股东大会审议。 4．审议通过了《公司 2023 年年度报告》全文和摘要 同意 5 票，反对 ...

目 录 | 一、审计报告……………………………………………………… 第 1—6 | | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 | | 页 | | （一）合并资产负债表…………………………………………… 第 | 7 | 页 | | （二）母公司资产负债表………………………………………… 第 | 8 | 页 | | （三）合并利润表………………………………………………… 第 | 9 | 页 | | （四）母公司利润表………………………………………………第 | 10 | 页 | | （五）合并现金流量表……………………………………………第 | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | 12 | 页 | | （七）合并所有者权益变动表……………………………………第 | 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 | 14 | 页 | | | | 审 计 报 告 天健审〔2024〕4256 号 浙江医药股份有限公司全体股东： 一、审计意见 我们审计了浙江医药股 ...

浙江医药股份有限公司章程 二○二四年四月二十五日 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据《中华人民 共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）和其他 有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下简称"公司"）。 公司经浙江省人民政府证券委员会浙证委[1997]57 号文批准，由原浙江新昌制药股份有限 公司、浙江仙居药业集团股份有限公司和浙江省医药有限公司新设合并组建，以募集方式设立； 在浙江省市场监督管理局注册登记，取得营业执照。营业执照号：91330000142943469Q。 第三条 公司于 1999 年 8 月 12 日经中国证券监督管理委员会证监发行字[1999]99 号文批 准，首次向社会公众发行人民币普通股 5800 万股，于 1999 年 10 月 21 日在上海证券交易所上市。 第四条 公司注册名称：浙江医药股份有限公司 ZHEJIANG MEDICINE CO.,LTD. 第五条 公司住所：绍兴滨海新城致远中大道 168 号 邮政编码：312366。 | 第 ...

浙江医药股份有限公司 独立董事 2023 年度述职报告 （夏 青） 作为浙江医药股份有限公司（以下简称"公司"）独立董事，本着为全体股 东负责的精神，严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公 司独立董事规则》等法律法规的规定和要求，并以《公司章程》和《公司独立董 事制度》为指引，忠实履行了独立董事职责，主动了解公司的经营情况，对重大 事项发表意见、提出建议，切实维护了公司及股东，尤其是中小股东的合法权益。 现将 2023 年度履职情况报告如下： 一、独立董事基本情况 （一）工作履历及专业背景 本人夏青，1977 年生，中国农工党员，博士研究生学历，教授。主要研究 前沿生物技术及再生医学。曾在美国南加州大学和美国哈佛医学院学习。2006 年起在北京大学药学院工作，2022 年北京大学药学院长聘教授。 （二）独立性情况说明 经过自查，我对自身的独立性情况进行以下说明： 作为公司的独立董事，除在公司担任独立董事以外，本人及直系亲属、主要 社会关系均不在公司或其附属企业任职，未直接或间接持有公司已发行股份比例 1%以上，不是公司前十名股东，不在直接或间接持有公司已发行股份 5%以上的 股东单位或 ...

关于减少公司注册资本并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）于2024年4月25日召开公司第 九届十七次董事会，审议通过了《关于减少公司注册资本及修订<公司章程>的议 案》等议案。现将相关情况公告如下： 证券代码：600216 证券简称：浙江医药 公告编号：2024-008 浙江医药股份有限公司 除上述修订外，《公司章程》其他内容不变。修订后的《公司章程》详见上 海证券交易所网站（www.sse.com.cn）。 根据公司2022年第一次临时股东大会审议通过的《关于提请股东大会授权董 事会办理公司第二期限制性股票激励计划相关事宜的议案》的相关授权，本次注 1 册资本减少和公司章程修订事宜无需提交公司股东大会审议。本次变更内容和相 关章程条款的修订最终以工商行政管理机关核准的内容为准。 特此公告。 根据《上市公司股权激励管理办法》及《公司第二期限制性股票激励计划》 的相关规定，鉴于13名激励对象因个人原因已离职，不再具备激励对象资格；同 时鉴于第二个 ...

浙江医药股份有限公司 独立董事 2023 年度述职报告 （裘益政） （一）工作履历及专业背景 本人裘益政，1974 年生，中共党员，博士研究生学历，教授。中国会计学 术高端人才，浙江省管理会计咨询专家，现任浙江工商大学会计学院党委书记。 2002 年 7 月至 2007 年 11 月任浙江工商大学讲师，2007 年 12 月至 2010 年 12 月 任浙江工商大学财务系主任，2011 年 1 月至 2019 年 12 月任浙江工商大学会计 学院副院长，2010 年 1 月至 2022 年 11 月任浙江工商大学金融学院党委书记。 2022 年 12 月至今任浙江工商大学会计学院党委书记。 （二）独立性情况说明 经过自查，我对自身的独立性情况进行以下说明： 作为公司的独立董事，除在公司担任独立董事以外，本人及直系亲属、主要 社会关系均不在公司或其附属企业任职，未直接或间接持有公司已发行股份比例 1%以上，不是公司前十名股东，不在直接或间接持有公司已发行股份 5%以上的 股东单位或公司前五名股东单位任职。本人及直系亲属不在公司控股股东、公司 实际控制人及其附属企业任职，不存在与其有重大业务往来的情形，也不在与其 ...